Literature DB >> 23541141

[Severe cholestatic hepatitis revealing a DRESS syndrome].

N Droz1, M Thiebaut, B Terrier, A Bérézné, P Sogni, F Beuvon, L Guillevin, L Mouthon.   

Abstract

INTRODUCTION: Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome is a drug-induced hypersensitivity syndrome, characterized by rash, hyereosinophilia and multiorgan failure, including cytolytic hepatitis. CASE REPORT: A 75-year-old man, treated with amoxicillin/clavulanic acid, presented with jaundice and disabling pruritus associated with severe cholestatic hepatitis, related to a DRESS syndrome. Because of the persistence of cholestasis and the severity of pruritus, a treatment with corticosteroids and plasma exchanges was initiated, allowing a rapid and complete remission.
CONCLUSION: Amoxicillin/clavulanic acid, although rarely described in the literature, is a rare cause of DRESS syndrome. Severe cholestatic hepatitis associated with disabling pruritus may be one of the systemic manifestations, with a good prognosis using corticosteroids and plasma exchanges.
Copyright © 2013 Société nationale française de médecine interne (SNFMI). Published by Elsevier SAS. All rights reserved.

Entities:  

Keywords:  Amoxicillin/clavulanic acid; Amoxicilline/acide clavulanique; Cholestatic hepatitis; DRESS; Hépatite cholestatique; Plasma exchanges; Prurit; Pruritus; Échanges plasmatiques

Mesh:

Year:  2013        PMID: 23541141     DOI: 10.1016/j.revmed.2013.02.034

Source DB:  PubMed          Journal:  Rev Med Interne        ISSN: 0248-8663            Impact factor:   0.728


  2 in total

1.  [DRESS syndrome: report of three cases].

Authors:  Wafa Chebbi; Jihed Souissi; Jihène Chelli; Fatma Larbi; Baha Zantour; Mohamed Habib Sfar
Journal:  Pan Afr Med J       Date:  2014-10-17

Review 2.  Antibacterial antibiotic-induced drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome: a literature review.

Authors:  Shiva Sharifzadeh; Amir Hooshang Mohammadpour; Ashraf Tavanaee; Sepideh Elyasi
Journal:  Eur J Clin Pharmacol       Date:  2020-10-06       Impact factor: 2.953

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.